Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Saved in:
| Title: | Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. |
|---|---|
| Authors: | Ferrante, Marc1 (AUTHOR) marc.ferrante@uzleuven.be, D'Haens, Geert2 (AUTHOR), Jairath, Vipul3 (AUTHOR), Danese, Silvio4 (AUTHOR), Chen, Minhu5 (AUTHOR), Ghosh, Subrata6 (AUTHOR), Hisamatsu, Tadakazu7 (AUTHOR), Kierkus, Jaroslaw8 (AUTHOR), Siegmund, Britta9 (AUTHOR), Bragg, Sonja Michelle10 (AUTHOR), Crandall, Wallace10 (AUTHOR), Durand, Frederick10 (AUTHOR), Hon, Emily10 (AUTHOR), Lin, Zhantao10 (AUTHOR), Lopes, Michelle Ugolini10 (AUTHOR), Morris, Nathan10 (AUTHOR), Protic, Marijana10 (AUTHOR), Carlier, Hilde10 (AUTHOR), Sands, Bruce E11 (AUTHOR) |
| Source: | Lancet. Dec2024, Vol. 404 Issue 10470, p2423-2436. 14p. |
| Database: | Business Source Ultimate |
Be the first to leave a comment!
